Well-defined nonmigrating polymeric plasticizers, poly(vinyl chloride)- block -polycaprolactone (PVC- b -PCL), were synthesized by sequential reversible addition–fragmentation chain transfer (RAFT) polymerization and ring-opening polymerization (ROP) with 2-hydroxyethyl 2-(ethoxycarbonothioylthio)propanoate (HECP) as RAFT agent and incipient initiator for ROP of ε-caprolactone (CL, oxepan-2-one). Kinetic experiments demonstrated that HECP provided good control in RAFT polymerization of vinyl chloride (VC) with dispersity ( Đ ) ∼ 1.2 for 3400 < M n < 11000. Chain extension experiments with VC and vinyl acetate proved the high end-group fidelity of the macroRAFT agent formed. The hydroxy end-group of the PVC macroRAFT agent allowed its use as a ROP initiator in forming a series of PVC- b -PCL with different PCL block lengths by RAFT-T̵-ROP. Characterization by wide-angle X-ray diffraction (WAXD), polarized light microscopy (PLM), and differential scanning calorimetry (DSC) indicates that there is enhanced chain entanglement for PVC- b -PCL block copolymers when compared to PCL homopolymers in PVC blends, which accounts for PVC- b -PCL being able to provide permanent plasticization. The PVC- b -PCL copolymers are also effective as polymeric compatibilizers in PVC/PCL blends where they suppress the migration of PCL. PVC blends plasticized with PVC- b -PCL show similar or better ductility than PVC containing the archetypical PVC plasticizer dioctyl phthalate (DOP) for the same level of plasticizer. Most importantly, the PVC- b -PCL polymeric plasticizers are nonleaching and do not migrate under conditions where DOP is readily extractable.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: